Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age

Susanna Esposito, Alessandro Lizioli, Annalisa Lastrico, Enrica Begliatti, Alessandro Rognoni, Claudia Tagliabue, Laura Cesati, Vittorio Carreri, Nicola Principi

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Medical and public health importance of pneumococcal infections justifies the implementation of measures capable of reducing their incidence and severity, and explains why the recently marketed heptavalent pneumococcal conjugate vaccine (PCV-7) has been widely studied by pediatricians. This study was designed to evaluate the impact of PCV-7 administered at 3, 5 and 11 months of age on respiratory tract infections in very young children.Methods: A total of 1,571 healthy infants (910 males) aged 75-105 days (median 82 days) were enrolled in this prospective cohort trial to receive a hexavalent vaccine (DTaP/IPV/HBV/Hib) and PCV-7 (n = 819) or the hexavalent vaccine alone (n = 752) at 3, 5 and 11 months of age. Morbidity was recorded for the 24 months following the second dose by monthly telephone interviews conducted by investigators blinded to the study treatment assignment using standardised questionnaires. During these interviews, the caregivers and the children's pediatricians were questioned about illnesses and the use of antibiotics since the previous telephone call. All of the data were analysed using SAS Windows v.12.Results: Among the 1,555 subjects (98.9%) who completed the study, analysis of the data by the periods of follow-up demonstrated that radiologically confirmed community-acquired pneumonia (CAP) was significantly less frequent in the PCV-7 group during the follow-up as a whole and during the last period of follow-up. Moreover, there were statistically significant between-group differences in the incidence of acute otitis media (AOM) in each half-year period of follow-up except the first, with significantly lower number of episodes in children receiving PCV-7 than in controls. Furthermore, the antibiotic prescription data showed that the probability of receiving an antibiotic course was significantly lower in the PCV-7 group than in the control group.Conclusion: Our findings show the effectiveness of the simplified PCV-7 schedule (three doses administered at 3, 5 and 11-12 months of age) in the prevention of CAP and AOM, diseases in which Streptococcus pneumoniae plays a major etiological role. A further benefit is that the use of PCV-7 reduces the number of antibiotic prescriptions. All of these advantages may also be important from an economic point of view.

Original languageEnglish
Article number12
JournalRespiratory Research
Volume8
DOIs
Publication statusPublished - Feb 21 2007

Fingerprint

Respiratory Tract Infections
Anti-Bacterial Agents
Otitis Media
Prescriptions
Pneumonia
Interviews
Pneumococcal Infections
Incidence
Streptococcus pneumoniae
Telephone
Caregivers
Appointments and Schedules
Vaccines
Public Health
Economics
Research Personnel
Demography
Morbidity
Control Groups
Heptavalent Pneumococcal Conjugate Vaccine

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. / Esposito, Susanna; Lizioli, Alessandro; Lastrico, Annalisa; Begliatti, Enrica; Rognoni, Alessandro; Tagliabue, Claudia; Cesati, Laura; Carreri, Vittorio; Principi, Nicola.

In: Respiratory Research, Vol. 8, 12, 21.02.2007.

Research output: Contribution to journalArticle

Esposito, Susanna ; Lizioli, Alessandro ; Lastrico, Annalisa ; Begliatti, Enrica ; Rognoni, Alessandro ; Tagliabue, Claudia ; Cesati, Laura ; Carreri, Vittorio ; Principi, Nicola. / Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. In: Respiratory Research. 2007 ; Vol. 8.
@article{265f132108cf468e8998ba003221bd0d,
title = "Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age",
abstract = "Background: Medical and public health importance of pneumococcal infections justifies the implementation of measures capable of reducing their incidence and severity, and explains why the recently marketed heptavalent pneumococcal conjugate vaccine (PCV-7) has been widely studied by pediatricians. This study was designed to evaluate the impact of PCV-7 administered at 3, 5 and 11 months of age on respiratory tract infections in very young children.Methods: A total of 1,571 healthy infants (910 males) aged 75-105 days (median 82 days) were enrolled in this prospective cohort trial to receive a hexavalent vaccine (DTaP/IPV/HBV/Hib) and PCV-7 (n = 819) or the hexavalent vaccine alone (n = 752) at 3, 5 and 11 months of age. Morbidity was recorded for the 24 months following the second dose by monthly telephone interviews conducted by investigators blinded to the study treatment assignment using standardised questionnaires. During these interviews, the caregivers and the children's pediatricians were questioned about illnesses and the use of antibiotics since the previous telephone call. All of the data were analysed using SAS Windows v.12.Results: Among the 1,555 subjects (98.9{\%}) who completed the study, analysis of the data by the periods of follow-up demonstrated that radiologically confirmed community-acquired pneumonia (CAP) was significantly less frequent in the PCV-7 group during the follow-up as a whole and during the last period of follow-up. Moreover, there were statistically significant between-group differences in the incidence of acute otitis media (AOM) in each half-year period of follow-up except the first, with significantly lower number of episodes in children receiving PCV-7 than in controls. Furthermore, the antibiotic prescription data showed that the probability of receiving an antibiotic course was significantly lower in the PCV-7 group than in the control group.Conclusion: Our findings show the effectiveness of the simplified PCV-7 schedule (three doses administered at 3, 5 and 11-12 months of age) in the prevention of CAP and AOM, diseases in which Streptococcus pneumoniae plays a major etiological role. A further benefit is that the use of PCV-7 reduces the number of antibiotic prescriptions. All of these advantages may also be important from an economic point of view.",
author = "Susanna Esposito and Alessandro Lizioli and Annalisa Lastrico and Enrica Begliatti and Alessandro Rognoni and Claudia Tagliabue and Laura Cesati and Vittorio Carreri and Nicola Principi",
year = "2007",
month = "2",
day = "21",
doi = "10.1186/1465-9921-8-12",
language = "English",
volume = "8",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age

AU - Esposito, Susanna

AU - Lizioli, Alessandro

AU - Lastrico, Annalisa

AU - Begliatti, Enrica

AU - Rognoni, Alessandro

AU - Tagliabue, Claudia

AU - Cesati, Laura

AU - Carreri, Vittorio

AU - Principi, Nicola

PY - 2007/2/21

Y1 - 2007/2/21

N2 - Background: Medical and public health importance of pneumococcal infections justifies the implementation of measures capable of reducing their incidence and severity, and explains why the recently marketed heptavalent pneumococcal conjugate vaccine (PCV-7) has been widely studied by pediatricians. This study was designed to evaluate the impact of PCV-7 administered at 3, 5 and 11 months of age on respiratory tract infections in very young children.Methods: A total of 1,571 healthy infants (910 males) aged 75-105 days (median 82 days) were enrolled in this prospective cohort trial to receive a hexavalent vaccine (DTaP/IPV/HBV/Hib) and PCV-7 (n = 819) or the hexavalent vaccine alone (n = 752) at 3, 5 and 11 months of age. Morbidity was recorded for the 24 months following the second dose by monthly telephone interviews conducted by investigators blinded to the study treatment assignment using standardised questionnaires. During these interviews, the caregivers and the children's pediatricians were questioned about illnesses and the use of antibiotics since the previous telephone call. All of the data were analysed using SAS Windows v.12.Results: Among the 1,555 subjects (98.9%) who completed the study, analysis of the data by the periods of follow-up demonstrated that radiologically confirmed community-acquired pneumonia (CAP) was significantly less frequent in the PCV-7 group during the follow-up as a whole and during the last period of follow-up. Moreover, there were statistically significant between-group differences in the incidence of acute otitis media (AOM) in each half-year period of follow-up except the first, with significantly lower number of episodes in children receiving PCV-7 than in controls. Furthermore, the antibiotic prescription data showed that the probability of receiving an antibiotic course was significantly lower in the PCV-7 group than in the control group.Conclusion: Our findings show the effectiveness of the simplified PCV-7 schedule (three doses administered at 3, 5 and 11-12 months of age) in the prevention of CAP and AOM, diseases in which Streptococcus pneumoniae plays a major etiological role. A further benefit is that the use of PCV-7 reduces the number of antibiotic prescriptions. All of these advantages may also be important from an economic point of view.

AB - Background: Medical and public health importance of pneumococcal infections justifies the implementation of measures capable of reducing their incidence and severity, and explains why the recently marketed heptavalent pneumococcal conjugate vaccine (PCV-7) has been widely studied by pediatricians. This study was designed to evaluate the impact of PCV-7 administered at 3, 5 and 11 months of age on respiratory tract infections in very young children.Methods: A total of 1,571 healthy infants (910 males) aged 75-105 days (median 82 days) were enrolled in this prospective cohort trial to receive a hexavalent vaccine (DTaP/IPV/HBV/Hib) and PCV-7 (n = 819) or the hexavalent vaccine alone (n = 752) at 3, 5 and 11 months of age. Morbidity was recorded for the 24 months following the second dose by monthly telephone interviews conducted by investigators blinded to the study treatment assignment using standardised questionnaires. During these interviews, the caregivers and the children's pediatricians were questioned about illnesses and the use of antibiotics since the previous telephone call. All of the data were analysed using SAS Windows v.12.Results: Among the 1,555 subjects (98.9%) who completed the study, analysis of the data by the periods of follow-up demonstrated that radiologically confirmed community-acquired pneumonia (CAP) was significantly less frequent in the PCV-7 group during the follow-up as a whole and during the last period of follow-up. Moreover, there were statistically significant between-group differences in the incidence of acute otitis media (AOM) in each half-year period of follow-up except the first, with significantly lower number of episodes in children receiving PCV-7 than in controls. Furthermore, the antibiotic prescription data showed that the probability of receiving an antibiotic course was significantly lower in the PCV-7 group than in the control group.Conclusion: Our findings show the effectiveness of the simplified PCV-7 schedule (three doses administered at 3, 5 and 11-12 months of age) in the prevention of CAP and AOM, diseases in which Streptococcus pneumoniae plays a major etiological role. A further benefit is that the use of PCV-7 reduces the number of antibiotic prescriptions. All of these advantages may also be important from an economic point of view.

UR - http://www.scopus.com/inward/record.url?scp=36749094835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749094835&partnerID=8YFLogxK

U2 - 10.1186/1465-9921-8-12

DO - 10.1186/1465-9921-8-12

M3 - Article

VL - 8

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

M1 - 12

ER -